ABEO rises after Roth Capital initiates Buy; Fayuvi FDA approval
ABEO closed up 4% Thursday and added 2% after-hours after Roth Capital initiated coverage at Buy with a $17 target; Ultragenyx’s Fayuvi gene therapy received late-session FDA approval.
Shares of Abeona Therapeutics (ABEO) finished Thursday's regular session up 4% and gained another 2% after hours after Roth Capital started coverage with a Buy rating and a $17 target. Ultragenyx also won late-session FDA approval for Fayuvi, a gene therapy Abeona licensed away in 2022 and will collect royalties from.